Latest News
Tiziana files Registration Statement on Form F-3 with U.S. Securities and Exchange Commission
27 January 2021
New York / London, January 27, 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces that it has filed a “universal” shelf...
Updated corporate presentation
26 January 2021
New York/London, 26 January 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, has today published an updated presentation to...
AIM Delisting and Admission to the Standard Listing Segment of Main Market
20 January 2021
New York/London, 20 January 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today provided a further update with respect to...
Appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer
13 January 2021
New York/London, 13 January 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces the appointment of Dr Neil Graham MBBS,...
Tiziana Life Sciences to participate at J.P. Morgan Healthcare Conference 2021
11 January 2021
NEW YORK and LONDON – 11 January 2021 (GLOBE NEWSWIRE) – Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announced that...
Tiziana Life Sciences to Present at Biotech Showcase Digital 2021
11 January 2021